Theravance Bioph Stock Price, News & Analysis

Theravance Biopharma (TBPH) reported Q4 2021 revenues of $14.9 million, a decline of $3.8 million from the previous year. YUPELRI sales showed a 13% increase, gaining a 23.2% market share in the long-acting nebulized COPD market. Global sales for GSK's TRELEGY, in which Theravance holds economic interest, grew 52% year-over-year to $479 million for Q4. The company expects full-year 2022 R&D and SG&A expenses to decline, aiming for cash-flow positivity in H2 2022. The operating loss for Q4 decreased to $56.2 million, reflecting improved cost management.

Theravance Biopharma (NASDAQ: TBPH) will participate in the Respiratory/Infections Corporate Panel Discussion at the Cowen 42nd Annual Health Care Conference on March 8, 2022, at 2:10 pm ET. A live webcast will be available on their website, with a replay archived for 30 days. Theravance focuses on developing innovative respiratory medicines, including the FDA-approved YUPELRI® for COPD. The company also has an economic interest in future payments from Glaxo Group Limited related to certain programs, including TRELEGY.

Theravance Biopharma (NASDAQ: TBPH) is set to disclose its Q4 2021 and full year 2021 financial results on February 23, 2022, after market close. A conference call will follow at 5:00 PM ET. The company specializes in respiratory medicines and has developed the FDA-approved YUPELRI for COPD patients. It also has economic interests related to Glaxo Group Limited's programs, notably TRELEGY. The financial results and business updates will be crucial for investors monitoring TBPH's growth trajectory.

Theravance Biopharma (NASDAQ: TBPH) will present at the SVB Leerink 11th Annual Global Healthcare Conference on February 16, 2022, at 3:40 pm ET. A webcast of the event is available on Theravance.com and will be archived for 30 days.

Theravance Biopharma focuses on developing respiratory medicines, with its flagship product being YUPELRI®, an FDA-approved inhalation solution for chronic obstructive pulmonary disease (COPD). The company is also associated with potential payments from Glaxo Group Limited through agreements with Innoviva, Inc..

Theravance Biopharma (NASDAQ: TBPH) has enrolled the first patient in a Phase 4 study for YUPELRI® (revefenacin), a once-daily nebulized bronchodilator for COPD treatment. The PIFR-2 study aims to compare lung function improvements in patients using YUPELRI versus SPIRIVA® over 12 weeks, involving 366 participants. Results are expected in Q1 2023. This initiative seeks to expand YUPELRI’s market reach, enhancing its competitive position alongside the strategic collaboration with Viatris for commercialization.

Theravance Biopharma (NASDAQ: TBPH) will present at the J.P. Morgan 40th Annual Healthcare Conference on January 13, 2022, at 12:00 PM ET. The webcast can be accessed on the company's website under the Investors section, and a replay will be available for 30 days. Theravance focuses on respiratory medicines, boasting FDA-approved YUPELRI® for COPD. The company is committed to developing transformative therapies to improve respiratory health.

Theravance Biopharma (NASDAQ: TBPH) will participate in the Evercore ISI 4th Annual HEALTHCONx Virtual Conference on November 30, 2021, at 11:20 am ET. The webcast can be accessed under the Investors section on Theravance.com and will be available for 30 days afterward. The biopharmaceutical company focuses on developing respiratory medicines, including the FDA-approved YUPELRI (revefenacin) for treating COPD. The company aims to enhance patient lives through innovative respiratory therapies.

Theravance Biopharma (TBPH) reported Q3 2021 financial results, showing total revenue of $13.2 million, down $5.1 million from Q3 2020. The decrease was primarily due to reduced collaboration revenue from Janssen. YUPELRI revenue was $10.4 million, reflecting a 7% year-over-year increase. The company aims for cash-flow positivity by H2 2022, planning a 75% workforce reduction by February 2022. R&D expenses decreased to $43.7 million from $67.4 million year-over-year, while operating loss improved to $53.6 million from $76.6 million.

Theravance Biopharma (NASDAQ: TBPH) will report its third quarter 2021 financial results on November 3, 2021, after market close. A conference call will follow at 5:00 PM ET. The call can be accessed by dialing (855) 296-9648 domestically or (920) 663-6266 internationally, using confirmation code 9772385. Company highlights include its focus on respiratory medicines and notable products like YUPELRI for COPD. Future financial benefits may arise from agreements with GSK related to certain programs.